Results of
$PFE 🔹 Revenue: $16.6B (Est. $15.87B) 🟢; flat year over year
🔹 Adjusted EPS: $0.87 (Est. $0.73) 🟢; flat year over year
🔹 GAAP EPS: $0.56; down 9% year over year
Raises FY26 guidance:
🔹 Revenue: $62.00B-$64.00B (Est. $62.17B) 🟡
🔹 Adjusted EPS: $2.95-$3.05 (Est. $2.96) 🟡
Other Q3 metrics:
🔹 Ex-COVID revenue: +7% operationally
🔹 Launched and acquired products: +32% operationally
Key updates:
🔹 CFO: Cecile Guegan appointed effective Nov. 1
Comments:
🔸 “Our obesity program continued to advance, and recent milestones in oncology, immunology, and vaccines further demonstrate the potential of our pipeline. With a strong lineup of anticipated catalysts ahead, I believe we are well positioned to deliver meaningful new medicines for patients and lasting value in the years to come.”
What do you think of the results? Let us know in the comments ⬇️⬇️
#CRIPTOMONEDASYACCIONES #USMidtermElections #PFEUSDT #BinanceSquareTalks #Write2Earn